GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biocytogen Pharmaceuticals (Beijing) Co 2315.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

41.70

+0.29%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.61bn

FY2020FY2025

Net income

CN¥201.7m

FY2020FY2025

Free cash flow

CN¥329.0m

FY2020FY2025

Shareholders' equity

CN¥2.53bn

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
RevenueCN¥1.61bnCN¥980.5mCN¥716.9mCN¥533.9mCN¥354.6mCN¥253.5m
Gross profitCN¥1.22bnCN¥761.5mCN¥506.0mCN¥391.8mCN¥247.4mCN¥167.0m
Research and developmentCN¥510.3mCN¥323.9mCN¥474.4mCN¥699.2mCN¥558.5mCN¥276.3m
Operating incomeCN¥324.5mCN¥128.7m−CN¥290.5m−CN¥604.6m−CN¥518.7m−CN¥362.6m
Net incomeCN¥201.7mCN¥33.5m−CN¥383.0m−CN¥602.2m−CN¥545.6m−CN¥543.0m
Diluted earnings per share0.500.08-0.96-1.56-1.50-1.37

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assetsCN¥4.34bnCN¥2.81bnCN¥2.85bnCN¥3.26bnCN¥2.68bnCN¥2.33bn
Cash and short-term investmentsCN¥1.82bnCN¥444.0mCN¥475.3mCN¥712.0mCN¥659.8mCN¥957.4m
Total liabilitiesCN¥1.80bnCN¥1.84bnCN¥1.93bnCN¥1.92bnCN¥1.22bnCN¥868.3m
DebtCN¥680.4mCN¥570.3mCN¥544.1mCN¥415.3mCN¥89.8mCN¥80.9m
Shareholders' equityCN¥2.53bnCN¥971.5mCN¥915.4mCN¥1.34bnCN¥1.45bnCN¥1.45bn
Shares outstanding400m398m398m387m364m397m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operationsCN¥431.3mCN¥211.2m−CN¥89.3m−CN¥353.2m−CN¥426.1m−CN¥225.3m
Capital spending−CN¥102.3m−CN¥37.1m−CN¥147.5m−CN¥280.3m−CN¥231.4m−CN¥306.4m
Free cash flowCN¥329.0mCN¥174.1m−CN¥236.8m−CN¥633.6m−CN¥657.5m−CN¥531.7m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023
RevenueCN¥1.08bnCN¥882.7mCN¥723.3mCN¥570.0mCN¥410.5mCN¥239.1mCN¥390.1mCN¥227.2m
Gross profitCN¥857.5mCN¥655.6mCN¥562.3mCN¥463.7mCN¥312.0mCN¥181.7mCN¥274.6mCN¥159.9m
Operating incomeCN¥310.1mCN¥199.4mCN¥125.1mCN¥149.6mCN¥14.7mCN¥8.6m−CN¥135.3m−CN¥78.8m
Net incomeCN¥277.0mCN¥145.8mCN¥55.9mCN¥84.2m−CN¥50.7m−CN¥29.5m−CN¥193.1m−CN¥112.5m
Diluted earnings per share0.620.360.140.21-0.13-0.07-0.48-0.28
Cash from operationsCN¥291.0mCN¥187.0mCN¥236.0mCN¥181.0mCN¥29.0mCN¥17.0m−CN¥68.0m−CN¥34.0m
Capital spending−CN¥253.0m−CN¥64.0m−CN¥36.0m−CN¥14.0m−CN¥22.0m−CN¥13.0m−CN¥42.0m−CN¥21.0m
Free cash flowCN¥38.0mCN¥123.0mCN¥200.0mCN¥167.0mCN¥7.0mCN¥4.0m−CN¥110.0m−CN¥55.0m
Total assetsCN¥4.24bnCN¥4.34bnCN¥2.90bnCN¥2.42bnCN¥2.43bnCN¥2.83bnCN¥2.45bnCN¥2.85bn
Cash and short-term investmentsCN¥1.21bnCN¥1.82bnCN¥567.1mCN¥381.2mCN¥391.9mCN¥494.0mCN¥408.1mCN¥505.6m
DebtCN¥270.8mCN¥680.4mCN¥715.4mCN¥570.3mCN¥575.2mCN¥287.3mCN¥544.1mCN¥236.7m
Shareholders' equityCN¥2.82bnCN¥2.53bnCN¥1.04bnCN¥834.1mCN¥739.7mCN¥861.6mCN¥785.9mCN¥915.4m

Financial ratios

Data as of 27 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin75.8%77.7%70.6%73.4%69.8%65.9%
Operating margin20.2%13.1%-40.5%-113.2%-146.3%-143.0%
Net margin12.6%3.4%-53.4%-112.8%-153.9%-214.2%
Return on equity8.0%4.0%-48.7%-52.5%-43.7%-37.4%
Return on assets4.7%1.4%-15.6%-21.5%-23.7%-23.3%
Free cash flow yield1.7%0.9%0.2%-0.2%-0.7%—
Revenue growth40.6%36.8%34.3%50.6%39.8%—
Earnings growth416.4%-108.8%-36.4%10.4%0.5%—
Current ratio2.31x1.53x1.25x1.52x1.96x3.49x
Debt to equity0.19x0.50x0.48x0.20x0.10x0.27x
Equity ratio58.4%34.5%32.1%40.9%54.2%62.5%
Interest coverage3.92x1.40x-2.91x-10.77x-13.16x-16.09x
R&D as a share of sales31.8%33.0%66.2%131.0%157.5%109.0%
Buybacks as a share of market value-0.6%0.1%-2.9%-6.2%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue48.3%60.6%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin76.5%75.0%74.0%—
Operating margin17.5%-11.5%-29.8%—
Net margin9.1%-19.5%-41.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings61.086.5-10.8-14.3
Price to sales8.43.57.019.2

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.